Today, only maintenance therapy is available to patients with hepatitis B. However, soon everything will change: American scientists discovered a protein, the effect of which can form the basis of drugs that defeat the virus.

Today, there are about 260 million people with chronic hepatitis B infection in the world. The disease significantly increases the risks of developing cirrhosis and liver cancer, and this requires regular medications that slow the development of irreversible damage. A new study by American scientists opens up prospects for a cure for hepatitis B.

Scientists have proven that apolipoprotein E (apoE) contributes to the infection and production of hepatitis B virus, writes EurekAlert. To cope with the virus, the team applied the effects of antibodies, suppressed the expression of apoE and turned off the apoE gene. Each approach successfully blocked the development of infection.

“These methods may be potential antiviral agents to eliminate chronic hepatitis B infection,” the authors said.

It was previously proven that apoE also plays an important role in the development of hepatitis C. Scientists suggest that apoE may play a role in chronic hepatitis B infection by evading immune cells, similar to its role in the life cycle of hepatitis C. The research will be continued.

In search of effective therapy against hepatitis B, scientists from France have found a way to destroy viral DNA. Their approach also has the potential to completely suppress the virus. Hepatitis B has been diagnosed in more than a quarter of a billion people. This viral disease is dangerous for its consequences. The main thing is chronic liver damage, the risk of cirrhosis and the further development of an organ tumor. French scientists at the Pasteur Institute have discovered a way to destroy viral DNA.

The DNase I protein they identified acts as a limiting factor. It can integrate into cellular mechanisms and prevent the virus from spreading.